“…↓, − indicates inhibition; ↑, +, stimulation; α,β, subunits of sGC; 20-HETE, 20-hydroxyeicosatetraenoic acid; AGE, advanced glycation end-products; AT II, angiotensin II; COX, cyclooxygenase; eNOS, endothelial nitric oxide synthase; H 2 S, hydrogen sulfide; LDL, low-density lipoproteins; MLCK, myosin light-chain kinase; NOX, nicotinamide adenine dinucleotide phosphate oxidase; SNO, S-nitrosylation; and XO, xanthine oxidase. by guest on May 10, 2018 http://circres.ahajournals.org/ Downloaded from on eNOS activity are prolonged exposure of the endothelial cells to increased levels of circulating aldosterone (leading to intracellular sodium accumulation thereby interrupting endothelial calcium-dependent signaling), cortisol (downregulating estrogen production), glucose (diverting glucose metabolism to the hexosamine pathway and thus increasing endothelial levels of N-acetylglucosamine which glycosylates eNOS), abnormal HDL (in patients with coronary artery disease), [128][129][130] carbamylated-HDL 125,131 (elevated in patients with end-stage renal disease and characterized by a reduced activity of the HDL-associated antioxidant enzyme paraoxonase I, and downregulating endothelial PI3K expression), high concentrations of dietary nitrate 132 (increasing eNOS phosphorylation at Thr495 and reducing that at Ser1177), the proinflammatory adipokine lipocalin-2 (in patients with obesity), the inflammatory mediator pentraxin 3 133 (activating the NFκB pathway), or progesterone (preventing the beneficial effect of estrogens). 15 Likewise, eNOS dysfunction can be favored by the relative absence of facilitating mediators such as adiponectin, angiotensin [1][2][3][4][5][6][7] (to judge from angiotensin-converting enzyme 2 deletion experiments), or apelin.…”